XNAS · Healthcare · Biotechnology
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-12 | Q3 2026 | -0.39 | -0.45 | -15.38% | $303,000 | ❌ Miss | -17.43% | +8.68% | +11.43% |
| 2025-11-13 | Q2 2026 | -0.47 | -0.54 | -14.89% | $258,000 | ❌ Miss | — | — | — |
| 2025-02-13 |
| Q3 2025 |
| -0.52 |
| -0.46 |
| +11.54% |
| $234,000 |
| ✅ Beat |
| +4.21% |
| +0.70% |
| -1.23% |
| 2024-11-07 | Q2 2025 | -0.39 | -0.42 | -7.69% | $183,000 | ❌ Miss | +0.64% | -12.50% | -16.99% |
| 2024-08-13 | Q1 2025 | -0.40 | -0.35 | +12.50% | $84,000 | ✅ Beat | -3.24% | +5.90% | -5.90% |
| 2024-06-11 | Q4 2024 | -0.37 | -0.25 | +32.43% | $197,300 | ✅ Beat | -2.12% | -12.20% | +3.71% |
| 2024-02-13 | Q3 2024 | -0.30 | -0.22 | +26.67% | $411,400 | ✅ Beat | — | — | — |
| 2023-08-10 | Q1 2024 | — | -0.94 | — | $177,600 | — | -14.57% | -26.28% | -11.51% |
Showing last 8 quarters.